Combination therapy for platelet recovery during cancer treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two medicines (hetrombopag and rhTPO) that help raise platelet counts, which often drop during cancer treatment. The goal is to see if this approach works well and is safe for people with low platelets caused by cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a solid tumor cancer (such as lung, breast, stomach, or colon cancer).
- You are currently receiving cancer treatment like chemotherapy, radiation, or targeted therapy.
- Your platelet count is below 50,000, which is considered a serious drop.
- You are generally able to take care of yourself (able to walk and manage daily activities).
- You have not had serious heart problems or blood clots in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
Hear when a new Cancer Therapy-induced Thrombocytopenia (CTIT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.